Compare ERC & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ERC | SGHT |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 309.6M |
| IPO Year | N/A | 2021 |
| Metric | ERC | SGHT |
|---|---|---|
| Price | $8.55 | $9.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 52.5K | ★ 185.8K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 8.37% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ 0.72 | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $11.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.47 | $3.19 |
| 52 Week High | $9.78 | $9.34 |
| Indicator | ERC | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 21.80 | 78.57 |
| Support Level | N/A | $4.43 |
| Resistance Level | $9.28 | N/A |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 11.47 | 89.69 |
Allspring Multi-Sector Income Fund is a closed-end investment management company. The company's core business is to secure a high level of income for its investors consistent with limiting its overall exposure to domestic interest rate risk. It invests in U.S. dollar-denominated below investment-grade bonds, debentures, and other income obligations, including loans and preferred stocks, developed and emerging market debt securities, including obligations of foreign governments or governmental entities, foreign corporations, or supranational agencies denominated in various currencies, asset backed securities and investment grade corporate bonds.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.